Latest Conference Articles

IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors

Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.

Dr Skoulidis on the Implications of the POSEIDON Trial of Tremelimumab Plus Durvalumab in NSCLC

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the clinical implications for data from the combination of tremelimumab plus durvalumab and chemotherapy in metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.

CYCLONE 1 Misses Primary End Point But Abemaciclib Shows Activity in mCRPC

Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer.

Molecular Analysis Needed to Guide Further Study of Olaparib Plus Ceralasertib in Pediatric Advanced Cancers

The combination of PARP and ATR inhibition with olaparib and ceralasertib was tolerable but showed limited efficacy in pediatric patients with advanced malignancies harboring DNA replication stress and DNA repair deficiencies, according to findings from arm N of the phase 1/2 AcSé-ESMART trial.

Pemigatinib Demonstrates Activity in Previously Treated Solid Tumors Harboring Activating FGFR Alterations

Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.

Dr Desai on the Efficacy of Divarasib Plus Cetuximab in KRAS G12C–Mutant CRC

Jayesh Desai, MBBS, FRACP, discusses efficacy data for the combination of divarasib plus cetuximab in patients with colorectal cancer harboring a KRAS G12C mutation from a phase 1B study.

Exome Sequencing Is A Feasible Way to Execute CDCT1 Genetic Condition Screening

Whole-exome sequencing successfully identified genetic conditions in patients who may have been missed by clinical guidelines.

Dr Bryant on Utilizing Nivolumab With SOC in Grade Group 5 Prostate Cancer

John Michael "JM" Bryant, MD, discusses the combination of nivolumab with standard of care in the management of patients with prostate cancer, detailing the results of the interim analysis of the phase 2 trial.

HECTOR Deep Learning Model Shows Predictability for Distant Recurrence Risk in Endometrial Cancer

A deep learning risk prediction model was able to accurately identify patients with endometrial cancer at low and high risk of distant recurrence, according to data presented during the 2023 AACR Annual Meeting.

Divarasib Plus Cetuximab Demonstrates Promising Clinical Activity and Manageable Safety in KRAS G12C–Mutant CRC

The selective, oral KRASG12C inhibitor divarasib demonstrated promising clinical activity in patients with colorectal cancer treated with the agent plus cetuximab.

Awareness of the HPV-Cancer Connection, Vaccine Rates Are Lagging

Fewer Americans are aware of the fact that the human papillomavirus can cause certain types of cancer, and vaccination rates against the virus are lagging, according to recent research presented at the AACR Annual Meeting 2023.

Dr Suvannasankha on the Safety/Efficacy of REGN5459 in R/R Multiple Myeloma

Attaya Suvannasankha, MD, discusses the safety and efficacy of REGN5459, a BCMAxCD3 bispecific antibody with low affinity to CD3 on T cells, in relapsed/refractory multiple myeloma.

IBI351 Demonstrates Early Antitumor Activity and Tolerability in KRAS G12C+ Advanced NSCLC

The recommended phase 2 dose of IBI351 monotherapy had favorable safety and encouraging efficacy signals when administered to patients with advanced KRAS G12C–mutated non­–small cell lung cancer, according to updated data from a phase 1 dose-escalation study.

Lifirafenib/Mirdametinib Combination Is Safe and Tolerable in Advanced/Refractory Solid Tumors

Lifirafenib plus mirdametinib produced a tolerable safety profile and antitumor activity in patients with BRAF- or KRAS-mutant advanced or refractory solid tumors.

Novel KRAS G12C Inhibitor Shows Early Signs of Efficacy Across Solid Tumors, Pretreated NSCLC

LY3537982, an investigative KRAS G12C inhibitor, demonstrated clinical efficacy across patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

BGB-3245 Displays Early Antitumor Activity in Advanced/Refractory Solid Tumors With MAPK Pathway Mutations

The RAF dimer inhibitor BGB-3245 generated early efficacy signals with a tolerable safety profile in patients with advanced or refractory solid tumors harboring MAPK pathway mutations.

ALLO-316 Demonstrates Antitumor Activity in Advanced Clear Cell RCC

The allogeneic anti-CD70 CAR T-cell therapy ALLO-316 elicited signals of antitumor activity and showed a tolerable safety profile in patients with advanced or metastatic clear cell renal cell carcinoma.

Dr Sabari on Preliminary Data From a Phase 1 Study of LY3537982 in KRAS G12C–mutant Advanced Solid Tumors

Joshua K. Sabari, MD, discusses key findings from the phase 1 LOXO-RAS-20001 study of the KRAS G12C inhibitor LY3537982 in KRAS G12C–mutant advanced solid tumors.

Dr Srour on the Phase 1 TRAVERSE Study of ALLO-316 in Metastatic Clear Cell RCC

Samer A. Srour, MB, ChB, MS, discusses the study design of the phase 1 TRAVERSE study, and key data on the use of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.

African Ancestry Is Associated With Fewer Actionable Alterations in CRC

Patients with African ancestry with colorectal cancer have fewer actionable gene mutations than those with European ancestry, leading to fewer targeted treatment options in this population.

Pembrolizumab Yields High Response Rates for Patients With Unresectable Metastatic Desmoplastic Melanoma

Patients with unresectable metastatic desmoplastic melanoma achieved high response rates when treated with single-agent pembrolizumab in the SWOG S1512 trial, according to data presented during the 2023 AACR Annual Meeting.

Selective CDK2 Inhibitor Undergoes Investigation in CCNE1-High Tumors

Preclinical data have demonstrated activity of a novel, small molecule CDK2 inhibitor INCB123667 in CDK2/cyclin E1 expressing cell lines prompting investigators to initiate a phase 1 study, and the agent may fill an unmet need for patients with cancers with primary or acquired CDK4/6 resistance.

AFM13 Exhibits Efficacy in CD30+ Relapsed/Refractory PTCL

The investigational tetravalent bispecific antibody AFM13 displayed clinical efficacy in heavily pretreated patients with CD30-positive relapsed/refractory peripheral T-cell lymphoma.

Tafasitamab Plus Lenalidomide Has Continued Efficacy and Safety in R/R DLBCL

The combination of tafasitamab and lenalidomide followed by tafasitamab maintenance prolonged responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr Heymach on Results from the AEGEAN Trial of Durvalumab in Resectable NSCLC

John V. Heymach, MD, PhD, discusses findings the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.

Dr Islam on Treatment of Patients With Hodgkin Lymphoma With or Without HIV

Jessica Yasmine Islam, PhD, MPH, discusses the treatment of patients with Hodgkin’s lymphoma who do or do not have HIV.

Perioperative Durvalumab Plus Neoadjuvant Chemo Improves pCR, EFS in Resectable NSCLC

Perioperative durvalumab plus neoadjuvant platinum-based chemotherapy demonstrated a statistically significant improvement in pathologic complete response and event-free survival vs placebo plus chemotherapy in patients with resectable non–small cell lung cancer.

Adjuvant mRNA-4157 Plus Pembrolizumab Improves RFS in Resected High-Risk Melanoma

mRNA-4157 in combination with pembrolizumab improved recurrence-free survival compared with pembrolizumab alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumor mutational burden.

Pembrolizumab Plus Cisplatin/Gemcitabine Extends OS in Advanced Biliary Tract Cancer

Pembrolizumab plus cisplatin and gemcitabine produced a statistically significant and clinically meaningful improvement in overall survival vs placebo plus cisplatin and gemcitabine in previously untreated patients with advanced biliary tract cancer, according to data from the phase 3 KEYNOTE-966 trial.

Adjuvant Atezolizumab Plus Bevacizumab Significantly Improves RFS in High-risk HCC

Adjuvant treatment with the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival vs active surveillance in patients with a high risk of hepatocellular carcinoma recurrence following curative-intent resection or ablation.